Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership

Telix Pharmaceuticals (ASX:TLX) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or “INSERM”) and the “Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic” (ARRONAX).

As quoted in the press release:

Under the research partnership, Telix will explore the feasibility of using several of its clinical targeting agents with astatine. Astatine is an “alpha emitter”, a very high-energy radionuclide that is capable of significantly altering the tumour microenvironment when attached to a molecular targeting agent that is specific for cancer cells. The agreement will fund sufficient staff and facility time to conduct a number of studies over a two-year period, including preparation for pilot clinical studies in the nuclear medicine department of University Hospital of Nantes. The agreement also accesses a portfolio of intellectual property that has been developed within the Nantes cluster that may lead to new products and indications for Telix’s therapeutic pipeline.

Telix Europe President Ms. Odile Jaume stated, “The Nantes nuclear research cluster is one of the finest translational environments in Europe, with a particular strength and capability in astatine, including production facilities and processes that are capable of making materials for human research. This collaboration has the potential to expand the clinical utility of Telix’s technology and build a set of ‘next generation’ products that may deliver even greater clinical utility to cancer patients.”

Click here to read the full press release.